Radiologists Urge Use of Medical Imaging and AI-Powered Solutions to Manage COVID-19

Recent high-profile cases of COVID-19 combined with the effort to aid in the ongoing battle  against the pandemic have prompted RADLogics to deploy the company’s AI (Artificial Intelligence)-Powered medical image analysis solution worldwide. The company urged U.S. clinicians to embrace medical imaging and emerging technologies such as AI. RADLogics has an AI-powered solution in place which has processed and analyzed thousands of suspected coronavirus cases globally. These efforts have eased the surging workload for radiology, ER, and ICU teams worldwide.

RADLogics strives to make its CT and X-ray AI-powered technology available to hospitals and healthcare systems throughout the U.S. This technology will assist in COVID-19 patient triage and management by providing quantitative analysis to clinical teams. Those patients who exhibit severe or worsening respiratory conditions are accurately assessed, allowing doctors to better triage patients based on those who urgently need intensive care such as ventilator support.

Moshe Becker, CEO and Co-Founder of RADLogics, said, “The use of CT and X-ray in the assessment and treatment plan for President Trump underscores the critical role that medical imaging must play in the fight against COVID-19. We must scale the capabilities of these medical imaging procedures rapidly to support clinicians, hospitals, and healthcare systems throughout the U.S. as they respond to the anticipated second wave of coronavirus and the roll-out of a potential vaccine. Now is the time for hospitals and healthcare providers to embrace and leverage the power of AI technologies and solutions to not only alleviate the increased burden associated with COVID-19 but to help support better outcomes by reducing burnout and errors while delivering better patient outcomes.”

Eliot Siegel, MD, Associate Vice Chair of Diagnostic Radiology and Nuclear Medicine at the University of Maryland School of Medicine said, “The ability of medical imaging – in combination with AI – to better discover and quantify the burden of COVID-19 has been well-documented. There would be tremendous clinical value in an AI algorithm that could establish and utilize a trajectory of change to predict which subset of patients might need more intense therapy such as medical ventilation, which subset of patients could be more confidently discharged, and predict subsequent clinical course. Today, there are many promising AI applications that have emerged that could allow us to address the major challenges that have hit the healthcare sector during the pandemic, and beyond as we plan to treat patients with COVID-related complications and as we provide diagnostic and therapeutic procedures that were delayed during the surge.”  

Acceletronics is an industry leader in delivering the best equipment performance and service reliability from CT Scanners and Linear Accelerators across all major brands and models. Call 610-524-3300 or visit our website: https://www.acceletronics.com.

 

Written by the digital marketing staff at Creative Programs & Systems: www.cpsmi.com.

Combined Study Results Indicate Possibilities for Lung Cancer Screening in New Zealand

Lung cancer screening might be one step closer to fruition in New Zealand thanks to newly discovered results by the University of Otago, published by medical journal BMJ Open. The indigenous Māori people of New Zealand are particularly susceptible to lung cancer, as their mortality rates are between three and four times higher than other ethnic groups. Around 450 Māori are diagnosed with lung cancer, and approximately 300 die from it yearly. If caught in the early stages, health outcomes for the Māori and other ethnic groups will undoubtedly improve.

To assess whether low-dose computerized tomography (LDCT) might be a cost-effective way to screen for lung cancer, Waitematā and Auckland DHBs collaborated with University of Otago researchers. Led by Associate Professor Sue Crengle (Kāi Tahu, Kāti Mamoe, Waitaha) from the University of Otago, the researchers used scientific modeling to estimate the benefits and costs of LDCT screening when it comes to a high-risk population. LDCT uses a small amount of radiation to produce an extremely clear three-dimensional image from a computerized x-ray.

"Having clarity about the cost-effectiveness of lung cancer screening provides further impetus to get this work started," Associate Professor Crengle says. "If this works for Māori, then it will work for everyone else as well."

Study findings suggested a national biennial lung cancer screening program is likely beneficial in terms of cost-effectiveness for not only the Māori but also the entire population of New Zealand. With early screening, the number of deaths will be reduced among the indigenous people. Countries with screening trials have seen a 20 to 26 percent reduction in lung cancer deaths.

For further reading, check out the original article by News Medical Life Sciences or the journal reference by BMJ Open.

 

Acceletronics is an industry leader in delivering the best equipment performance and service reliability from CT Scanners and Linear Accelerators across all major brands and models. Call 610-524-3300 or visit our website: https://www.acceletronics.com.

 

 

Written by the digital marketing staff at Creative Programs & Systems: www.cpsmi.com